## Kamaraj Karunanithi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4649868/publications.pdf

Version: 2024-02-01

		1684188	2053705
5	344	5	5
papers	citations	h-index	g-index
5	5	5	654
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Copy number evolution and its relationship with patient outcomeâ€"an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 2021, 35, 2043-2053.	7.2	23
2	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Medicine, 2021, 18, e1003454.	8.4	18
3	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, 2020, 106, haematol.2020.247130.	3.5	16
4	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e616-e629.	4.6	42
5	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 57-73.	10.7	245